Kamada/$KMDA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kamada
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Ticker
$KMDA
Sector
Primary listing
Employees
420
Headquarters
Rehovot, Israel
Website
Kamada Metrics
BasicAdvanced
$409M
21.93
$0.32
0.08
$0.20
5.70%
Price and volume
Market cap
$409M
Beta
0.08
52-week high
$9.16
52-week low
$5.17
Average daily volume
51K
Dividend rate
$0.20
Financial strength
Current ratio
4.004
Quick ratio
2.211
Long term debt to equity
3.673
Total debt to equity
4.391
Dividend payout ratio (TTM)
60.67%
Interest coverage (TTM)
34.11%
Profitability
EBITDA (TTM)
38.445
Gross margin (TTM)
43.62%
Net profit margin (TTM)
11.21%
Operating margin (TTM)
14.89%
Effective tax rate (TTM)
-1.27%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
4.39%
Return on equity (TTM)
7.44%
Valuation
Price to earnings (TTM)
21.929
Price to revenue (TTM)
2.383
Price to book
5.16
Price to tangible book (TTM)
10.32
Price to free cash flow (TTM)
12.787
Free cash flow yield (TTM)
7.82%
Free cash flow per share (TTM)
0.549
Dividend yield (TTM)
2.85%
Forward dividend yield
5.70%
Growth
Revenue change (TTM)
9.67%
Earnings per share change (TTM)
27.97%
3-year revenue growth (CAGR)
16.87%
10-year revenue growth (CAGR)
9.21%
3-year earnings per share growth (CAGR)
6.82%
10-year earnings per share growth (CAGR)
2.05%
What the Analysts think about Kamada
Analyst ratings (Buy, Hold, Sell) for Kamada stock.
Bulls say / Bears say
Kamada’s revenue for the first half of 2025 increased 11% year-over-year to $88.8 million, and adjusted EBITDA rose 35% to $22.5 million, supported by a diversified portfolio and strong cost management.
The U.S. FDA approved Kamada’s Houston plasma collection center for commercial operation, expected to generate $8 million–$10 million annually at full capacity, enhancing vertical integration and supply reliability.
Kamada reaffirmed its full-year 2025 revenue outlook of $178 million–$182 million and raised its adjusted EBITDA guidance to $40 million–$44 million after surpassing consensus estimates in H1.
Phase 2/3 data for inhaled AAT failed to achieve statistically significant results on primary and key secondary endpoints, raising doubts about the likelihood of success in the pivotal Phase 3 InnovAATe trial.
Cash flow from operating activities in Q2 2025 totaled $8.0 million, down from $14.0 million a year prior, highlighting possible working capital strains as the company grows.
A significant share of revenue growth is attributable to GLASSIA royalty payments, making Kamada reliant on third-party sales performance and subject to renewal risks associated with Takeda’s commercial strategies.
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Kamada Financial Performance
Revenues and expenses
Kamada Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kamada stock?
Kamada (KMDA) has a market cap of $409M as of September 14, 2025.
What is the P/E ratio for Kamada stock?
The price to earnings (P/E) ratio for Kamada (KMDA) stock is 21.93 as of September 14, 2025.
Does Kamada stock pay dividends?
Yes, the Kamada (KMDA) stock pays dividends to shareholders. As of September 14, 2025, the dividend rate is $0.2 and the yield is 5.7%. Kamada has a payout ratio of 60.67% on a trailing twelve-month basis.
When is the next Kamada dividend payment date?
The next Kamada (KMDA) dividend payment date is unconfirmed.
What is the beta indicator for Kamada?
Kamada (KMDA) has a beta rating of 0.08. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.